STK11、KEAP1与SMARCA4基因拷贝缺失:非鳞状非小细胞肺癌的临床病理特征及与免疫治疗联合或不联合化疗结局的关联
在3194例非鳞状非小细胞肺癌中,STK11缺失占14.7%、KEAP1缺失占13.5%、SMARCA4缺失占13.7%,这些缺失与较低的程序性死亡配体1表达及较高的疾病分期、肿瘤突变负荷和非整倍体相关。在767例接受化学免疫治疗的患者中,上述缺失与较差的客观缓解率、无进展生存期和总生存期相关,其影响与这些基因突变的影响相当。在1267例单独接受免疫检查点抑制剂治疗的患者中,这些缺失在Memorial Sloan Kettering Cancer Center队列未影响结局,但在Dana-Farber Cancer Institute队列的KRAS突变病例中通常与较差结局相关。
要点
- 非鳞状NSCLC中STK11、KEAP1、SMARCA4缺失频率分别为14.7%、13.5%、13.7%。
- 这些缺失与较低PD-L1表达及较高分期、肿瘤突变负荷、非整倍体相关。
- 化学免疫治疗中,这些缺失与较差的客观缓解率、无进展生存期和总生存期相关。
核心结论
- STK11、KEAP1和SMARCA4缺失与非鳞状NSCLC的独特临床病理特征、较低的程序性死亡配体1表达及较差的化学免疫治疗疗效相关。
研究设计与样本
- 在Dana-Farber Cancer Institute分析非鳞状NSCLC病例中STK11、KEAP1和SMARCA4缺失的临床病理相关性,共3194例。
- 使用The Cancer Genome Atlas评估mRNA和LKB1蛋白水平。
- 在Dana-Farber Cancer Institute和Memorial Sloan Kettering Cancer Center分析接受免疫检查点抑制剂联合或不联合化疗患者的临床结局,其中化学免疫治疗767例,单独免疫检查点抑制剂治疗1267例。
- 分析每种缺失时排除该基因突变的病例。
主要发现
- 3194例非鳞状NSCLC中,STK11缺失占14.7%,KEAP1缺失占13.5%,SMARCA4缺失占13.7%。
- 这些缺失与较低的程序性死亡配体1表达及较高的疾病分期、肿瘤突变负荷和非整倍体相关。
- STK11缺失、KEAP1缺失和SMARCA4缺失各自与相应mRNA表达较低相关,STK11缺失与LKB1蛋白表达较低相关。
- 767例接受化学免疫治疗患者中,STK11缺失组客观缓解率31% vs 无缺失组45%(p=0.005);KEAP1缺失组33% vs 45%(p=0.03);SMARCA4缺失组29% vs 45%(p=0.0007)。
- 767例接受化学免疫治疗患者中,STK11缺失组无进展生存期HR=1.5(p=0.0001),KEAP1缺失组HR=1.4(p=0.002),SMARCA4缺失组HR=1.6(p<0.0001);总生存期STK11缺失组HR=1.7(p<0.0001),KEAP1缺失组HR=1.5(p=0.003),SMARCA4缺失组HR=1.7(p<0.0001)。
关键数值与推荐
- STK11缺失:化学免疫治疗客观缓解率31% vs 45%(p=0.005),无进展生存期HR=1.5(p=0.0001),总生存期HR=1.7(p<0.0001)。
- KEAP1缺失:化学免疫治疗客观缓解率33% vs 45%(p=0.03),无进展生存期HR=1.4(p=0.002),总生存期HR=1.5(p=0.003)。
- SMARCA4缺失:化学免疫治疗客观缓解率29% vs 45%(p=0.0007),无进展生存期HR=1.6(p<0.0001),总生存期HR=1.7(p<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Mutations in STK11, KEAP1, and SMARCA4 predispose to inferior immune checkpoint inhibitor (ICI) efficacy in NSCLC, particularly among KRAS-mutant cases. Nevertheless, the frequency, clinicopathologic features, and clinical impact of deletions in these genes are poorly characterized. METHODS: Clinicopathologic correlates of STK11, KEAP1, and SMARCA4 deletion were analyzed in cases of nonsquamous NSCLC at Dana-Farber Cancer Institute (DFCI). mRNA and LKB1 protein levels were assessed using The Cancer Genome Atlas. Clinical outcomes were analyzed in patients who received ICI with or without chemotherapy at DFCI and Memorial Sloan Kettering Cancer Center. Analyses of each deletion excluded cases with mutations in that gene. RESULTS: Among the 3194 cases of nonsquamous NSCLC, 14.7% had STK11 deletion (STK11DEL), 13.5% KEAP1 deletion (KEAP1DEL), and 13.7% SMARCA4 deletion (SMARCA4DEL). These deletions correlated with lower programmed death-ligand 1 expression and higher disease stage, tumor mutational burden, and aneuploidy. STK11DEL, KEAP1DEL, and SMARCA4DEL each correlated with lower corresponding mRNA expression, and STK11DEL with lower LKB1 protein expression. Among 767 patients treated with chemoimmunotherapy, these deletions were associated with worse objective response rates (STK11 31% versus 45%, p = 0.005; KEAP1 33% versus 45%, p = 0.03; SMARCA4 29% versus 45%, p = 0.0007), progression-free survival (STK11 hazard ratio [HR] = 1.5, p = 0.0001; KEAP1 HR = 1.4, p = 0.002; SMARCA4 HR = 1.6, p < 0.0001), and overall survival (STK11 HR = 1.7, p < 0.0001; KEAP1 HR = 1.5, p = 0.003; SMARCA4 HR = 1.7, p < 0.0001). The effect of these deletions on chemoimmunotherapy outcomes was comparable to the effect of mutations in these genes. Among 1267 patients treated with ICI alone, these deletions did not impact outcomes in the Memorial Sloan Kettering Cancer Center cohort but were generally associated with worse outcomes in the DFCI cohort among KRAS-mutant cases. CONCLUSIONS: STK11, KEAP1, and SMARCA4 deletions correlate with distinct clinicopathologic features, reduced programmed death-ligand 1 expression, and poor chemoimmunotherapy efficacy in NSCLC.
引用
- Gandhi MM, Elkrief A, Moore CG, et al. Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Clinicopathologic Features and Association With the Outcomes of Immunotherapy With or Without Chemotherapy in Nonsquamous NSCLC. J Thorac Oncol. 2025. PMID: 39864548. doi:10.1016/j.jtho.2025.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。